Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q2 2024 Pharmacy & Infusion Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q2 2024 Pharmacy & Infusion Update

Q2-24 saw a continuation of the growing interest investors have for the infusion services sector and the services that accompany it, including specialty pharmacy. The underpinnings for the investment model center around the shift in site of care from the once dominate hospital setting to a mix of ambulatory (AIC), office-based (OIC), and home-based infusion services. While each of these outpatient settings has its own unique clinical and operational pros and cons, they all present the common themes of reduced cost to the healthcare system and increased convenience to patients, while maintaining or even improving upon clinical outcomes in certain cases.

To stem the loss in infusion-related revenue, hospitals and health systems have shown an increased willingness to develop joint venture agreements with the outpatient service providers in their markets, not dissimilar to what’s been see in ambulatory surgery centers.  This allows for preferred drug pricing to benefit the outpatient provider and is a way for the hospital to retain at least some of the infusion economics.

To print and download the full Pharmacy & Infusion Update report, please click below…

[holo_button icon=”/wp-content/uploads/2024/07/Q2-2024-Pharmacy-Infusion-vF.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]